Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
The two-drug combination of cyclophosphamide plus adriamycin was found to be therapeutically potentiating against four different C3H mammary tumor lines, the B16 melanoma, the Ridgway osteogenic sarcoma, and the P388 leukemia. The potentiation was not schedule dependent.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D002460:Cell Line; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D007942:Leukemia, Experimental / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014184:Transplantation, Homologous
D004317:Doxorubicin; D003520:Cyclophosphamide